CL2023003365A1 - Conjugado de anticuerpo cmprensivo de anticuerpo anti-p-cadherina y usos del mismo - Google Patents

Conjugado de anticuerpo cmprensivo de anticuerpo anti-p-cadherina y usos del mismo

Info

Publication number
CL2023003365A1
CL2023003365A1 CL2023003365A CL2023003365A CL2023003365A1 CL 2023003365 A1 CL2023003365 A1 CL 2023003365A1 CL 2023003365 A CL2023003365 A CL 2023003365A CL 2023003365 A CL2023003365 A CL 2023003365A CL 2023003365 A1 CL2023003365 A1 CL 2023003365A1
Authority
CL
Chile
Prior art keywords
antibody
comprehensive
cadherin
conjugate
antibody conjugate
Prior art date
Application number
CL2023003365A
Other languages
English (en)
Spanish (es)
Inventor
Shen Yuhong
Li Jie
Li Jing
Original Assignee
Biocity Biopharmaceutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocity Biopharmaceutics Co Ltd filed Critical Biocity Biopharmaceutics Co Ltd
Publication of CL2023003365A1 publication Critical patent/CL2023003365A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2023003365A 2021-05-13 2023-11-10 Conjugado de anticuerpo cmprensivo de anticuerpo anti-p-cadherina y usos del mismo CL2023003365A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2021093652 2021-05-13

Publications (1)

Publication Number Publication Date
CL2023003365A1 true CL2023003365A1 (es) 2024-06-07

Family

ID=84028119

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003365A CL2023003365A1 (es) 2021-05-13 2023-11-10 Conjugado de anticuerpo cmprensivo de anticuerpo anti-p-cadherina y usos del mismo

Country Status (10)

Country Link
US (1) US20240239885A1 (https=)
EP (1) EP4337702A1 (https=)
JP (1) JP2024519585A (https=)
KR (1) KR20240007939A (https=)
CN (1) CN117295770A (https=)
AU (1) AU2022273147A1 (https=)
CA (1) CA3218789A1 (https=)
CL (1) CL2023003365A1 (https=)
IL (1) IL308485A (https=)
WO (1) WO2022237874A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230119179A (ko) * 2020-12-10 2023-08-16 우시 바이올로직스 아일랜드 리미티드 P-캐드히린에 대한 항체 및 이의 용도
WO2026021443A1 (en) * 2024-07-23 2026-01-29 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug conjugates targeting cdh3 and preparation methods and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560597A4 (en) * 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
CA2763671A1 (en) * 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
US8703920B2 (en) * 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
CA2869704A1 (en) * 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
HK1215959A1 (en) * 2013-02-15 2016-09-30 Perseus Proteomics Inc. Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of same
TW201625692A (zh) * 2014-11-14 2016-07-16 諾華公司 抗體藥物結合物
US20190194315A1 (en) * 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
EP3322735A4 (en) * 2015-07-15 2019-03-13 Zymeworks Inc. ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS

Also Published As

Publication number Publication date
AU2022273147A1 (en) 2024-01-04
CN117295770A (zh) 2023-12-26
IL308485A (en) 2024-01-01
EP4337702A1 (en) 2024-03-20
KR20240007939A (ko) 2024-01-17
WO2022237874A1 (en) 2022-11-17
CA3218789A1 (en) 2022-11-17
US20240239885A1 (en) 2024-07-18
JP2024519585A (ja) 2024-05-17

Similar Documents

Publication Publication Date Title
CL2023003365A1 (es) Conjugado de anticuerpo cmprensivo de anticuerpo anti-p-cadherina y usos del mismo
MX385823B (es) Conjugados de anticuerpo-farmaco hidrofilicos.
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
GT200500054A (es) Conjugados de caliqueamicina
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
CL2019002858A1 (es) Conjugación de un fármaco citotóxico con enlace bis.
CL2025001142A1 (es) Anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, métodos terapéuticos y sus usos
MX2020004935A (es) Terapias con celulas inmunitarias multifuncionales.
CL2016001760A1 (es) Adc de duocarmicina que demuestran mayor actividad antitumoral in vivo.
CL2024002860A1 (es) Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso
MX2020012674A (es) Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion.
MX2010001247A (es) Agentes de imagenologia optica.
ECSP18010616A (es) Inmunoconjugados de il22
CL2021002838A1 (es) Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo.
MX2022006289A (es) Tratamiento de canceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12.
UY37669A (es) Conjugados de fármaco-anticuerpo (adc) anti-prlr y usos de los mismos
CO2024015383A2 (es) Agentes aglutinantes 5t4 y usos de los mismos
MX2018009461A (es) Conjugados de anticuerpo-medicamento que se enfocan a la uparap.
PH12022553333A1 (en) Markers for use in methods for treating cancers with antibody drug conjugates (adc)
CO2025003362A2 (es) Conjugados de fármacos anticuerpo anti-sez6
CO2024015381A2 (es) Conjugados anticuerpo-fármaco 5t4 y usos de los mismos
CL2025001036A1 (es) Anticuerpo anti-gucy2c y usos del mismo
MX2023009146A (es) Anticuerpos y usos de estos.
CO2025015432A2 (es) Conjugados anticuerpo-fármaco de steap2 y usos de estos
MX2024002407A (es) Anticuerpos y conjugados sirp-alfa.